Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MemphasysASX:MEM Equity-to-Asset is 0.39 as of Dec. 2025, which is 32% below its 10-year median of 0.57. The stock has 5 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Memphasys ranks worse than 76.64% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Memphasys's Total Stockholders Equity for the quarter that ended in Dec. 2025 was A$4.02 Mil. Memphasys's Total Assets for the quarter that ended in Dec. 2025 was A$10.45 Mil.
Therefore, Memphasys's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.39.
The historical rank and industry rank for Memphasys's Equity-to-Asset or its related term are showing as below:
ASX:MEM'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.06 Med: 0.57 Max: 0.89
Current: 0.39
During the past 13 years, the highest Equity to Asset Ratio of Memphasys was 0.89. The lowest was -0.06. And the median was 0.57.
ASX:MEM's Equity-to-Asset is ranked worse than 76.64% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.645
vs ASX:MEM: 0.39
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Memphasys Equity-to-Asset Related Terms
Memphasys Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Memphasys's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MEM vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Memphasys's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Memphasys Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Memphasys's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Memphasys's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Memphasys's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Memphasys (ASX:MEM) has a Equity-to-Asset of 0.39 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Memphasys and its competitors. This is 32% below median its historical median of 0.57. According to the industry distribution chart, Memphasys ranks #653 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 76.6%.
Is Memphasys' Equity-to-Asset too high?
Memphasys' current Equity-to-Asset of 0.39 is 32% below median its 10-year median of 0.57. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Memphasys' value of 0.39 is 39.5% below this industry median. Based on the distribution chart, Memphasys ranks #653 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Memphasys' Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Memphasys ranks #653 out of 852 companies for Equity-to-Asset. This places Memphasys in the lower half of its industry. The industry median Equity-to-Asset is 0.65. Memphasys' value of 0.39 is 39.5% below this benchmark. While the company's 10-year median is 0.57 vs. the industry median of 0.65, Memphasys has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Memphasys's current Equity-to-Asset of 0.39 is 39.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Memphasys and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Memphasys's current Equity-to-Asset is 0.39, which is 32% below median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Memphasys stock overvalued right now?
Memphasys (ASX:MEM) has a current Equity-to-Asset of 0.39. The current Equity-to-Asset is 0.39, which is 32% below median its 10-year median of 0.57 and 39.5% below the Medical Devices & Instruments industry median of 0.65. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Memphasys (ASX:MEM), the current Equity-to-Asset is 0.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Memphasys Ltd is an Australian reproductive biotechnology company developing and commercializing novel reproduction and fertility solutions for humans and animals. The products in its development pipeline include a range of devices, media, and in vitro diagnostic solutions. The company is currently focused on the commercialisation of its patented Felix System, a novel bio-separation technology for assisted reproduction, designed to revolutionise sperm separation in assisted reproductive technology (ART) by providing a rapid, gentle, and automated process. The group has only one operating segment, being Reproductive Technologies, the assets and liabilities of which are located in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MEM has been successfully added to your 
